PPI Inhibitor Kidney Damage
Proton pump inhibitors (PPIs) are a class of drugs used to relieve heartburn and acid reflux by reducing the amount of acid produced by the stomach. PPIs are relied on by more than 15 million Americans. However, patients taking PPIs may face an increased risk of developing severe health issues, including chronic kidney disease.
You may be entitled to compensation if you or a loved one developed chronic kidney disease or kidney failure after taking a PPI drug, including:
We want to help protect your legal rights. Don’t wait to take action—call or contact us online to get started now.
Heartburn Drugs Linked to Chronic Kidney Disease
A study published in JAMA Internal Medicine showed patients who took PPIs once per day have a 15 percent increased risk of chronic kidney disease. In the same study, patients who took PPIs twice per day were 46 percent more likely to develop chronic kidney disease.
Researchers also found that patients who took PPIs faced a 39 percent higher risk of chronic kidney disease over patients of similar health treated with H2 blockers, another type of drug used to treat heartburn and acid reflux.
Heartburn Drug Kidney Disease Lawsuits
If you or someone you love developed chronic kidney disease or experienced kidney failure after taking Nexium, Prevacid, Prilosec, Losec, Protonix, or Zegerid you may be entitled to compensation. Our team of attorneys is committed to providing the legal representation you deserve for your injuries. Call or contact us online to get the legal help you need, today.
Prilosec®, Losec®, and Nexium® are registered trademarks of AstroZeneca plc. Prevacid® is a registered trademark of Takeda Pharmaceuticals U.S.A., Inc. Protonix® is a registered trademark of Pfizer, Inc. Zegerid® is a registered trademark of Santarus, Inc. All trademarks are used to identify the products in question.
This law firm is not associated with, sponsored by, or affiliated with the American Medical Association; AstroZeneca plc; JAMA Internal Medicine; Pfizer, Inc.; Santarus, Inc.; or Takeda Pharmaceuticals U.S.A., Inc.